Results 1 to 10 of about 38,087 (194)

ESRI EMEA 2010

GEOmedia, 2010
ESRI EMEA User Conference 2010 The ESRI EMEA User Conference is held every two years, and after London 2008, '2010 edition was held in Rome Oct. 26 to 28.
Sandra Leonardi, Francesco Bartoli
doaj   +4 more sources

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks [PDF]

Rheumatology and Therapy
Introduction Studies evaluating the long-term comparative efficacy between biologic therapies for psoriatic arthritis (PsA) are scarce. Two biologic therapies, guselkumab and secukinumab, were evaluated up to 52 weeks in a mixed patient population ...
Suzy van Sanden, Agata Schubert, Barkha P. Patel, Miriam Zimmermann, Fareen Hassan   +4 more
doaj   +2 more sources

Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review [PDF]

BMC Pregnancy and Childbirth
Background Haemolytic disease of the foetus and newborn (HDFN) is an immune disorder driven by maternal alloimmunisation against foetal/newborn red blood cell antigens.
P. Maurice, J. McCallion, M. Fitzgibbon, J. N. Barthelmes, W. Karmous, E. J. Hardy, S. A. Mitchell, C. R. Mitchell, J. Lee, W. Noel, Andras Borsi, J. M. Jouannic   +11 more
doaj   +2 more sources

Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study [PDF]

Frontiers in Psychiatry
IntroductionTreatment resistant depression (TRD) affects approximately 10–30% of patients with major depressive disorder, and most patients with TRD do not respond to real-world treatments (RWT).
Albino J. Oliveira-Maia, Albino J. Oliveira-Maia, Benoît Rive, Yordan Godinov, Siobhán Mulhern-Haughey   +4 more
doaj   +2 more sources

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry

Frontiers in Psychiatry, 2023
BackgroundTreatment resistant depression (TRD) affects 10–30% of patients with major depressive disorder. In 4-week trials, esketamine nasal spray (NS) was efficacious vs.
Albino J. Oliveira-Maia, Albino J. Oliveira-Maia, Joachim Morrens, Benoit Rive, Yordan Godinov, Jedelyn Cabrieto, Nolen Perualila, Sebastien Barbreau, Siobhán Mulhern-Haughey   +8 more
doaj   +1 more source

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

Frontiers in Psychiatry, 2023
BackgroundThe efficacy of esketamine nasal spray (NS) as a rapid-acting agent for treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when both were given in addition to a newly initiated selective serotonin reuptake ...
Albino J. Oliveira-Maia, Albino J. Oliveira-Maia, Benoit Rive, Joachim Morrens, Yordan Godinov, Jedelyn Cabrieto, Nolen Perualila, Siobhán Mulhern-Haughey   +7 more
doaj   +1 more source

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

European Psychiatry, 2023
Introduction Treatment resistant depression (TRD) is estimated to affect 10–30% of patients with major depressive disorder (Al‑Harbi et al. Patient Prefer Adherence 2012; 6 369–88).
A. Reif, A. E. Anıl Yağcıoğlu, A. Luts, T. Messer, R. Nielsen, J. Buyze, T. Ito, Y. Kambarov, S. Mulhern Haughey, B. Rive, I. Usankova, C. von Holt, Y. Godinov   +12 more
doaj   +1 more source

Self-reported burden of caregiver of adults with depression: a cross-sectional study in five Western European countries

BMC Psychiatry, 2021
Background Caregiving in depression imposes a complex health and economic burden. Moreover, there is a paucity of studies examining the impact of caregiving for adult relatives with unipolar depression (CG-UD).
B. L. Balkaran, D. H. Jaffe, D. Umuhire, B. Rive, R. U. Milz   +4 more
doaj   +1 more source

SBERTiment: A New Pipeline to Solve Aspect Based Sentiment Analysis in the Zero-Shot Setting

Proceedings of the International Florida Artificial Intelligence Research Society Conference, 2023
The field of Natural Language Processing is gaining increased attention for the Aspect Based Sentiment Analysis task due to its ability to provide fine-grained information.
Matteo Muffo, Aldo Cocco, Edoardo Negri, Enrico Bertino, Devi Veena Sreekumar, Giorgio Pennesi, Riccardo Lorenzon   +6 more
doaj   +1 more source

A leadless pacemaker in the real‐world setting: Patient profile and performance over time

Journal of Arrhythmia, 2023
Background While prior Micra trials demonstrated a high implant success rate and favorable safety and efficacy results, changes in implant populations and safety over time is not well studied.
Paul R. Roberts, Nicolas Clémenty, Pierre Mondoly, Stefan Winter, Pierre Bordachar, David Sharman, Werner Jung, Romain Eschalier, Cathrin Theis, Pascal Defaye, Christopher Anderson, Aimée Pol, Kiah Butler, Christophe Garweg   +13 more
doaj   +1 more source